Basilea Pharmaceutica AG (BPMUF)
USD 51.0
(-5.56%)
USD 51.0
(-5.56%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 130.84 Million CHF | 6.23% |
| 2022 | 123.16 Million CHF | -0.72% |
| 2021 | 124.05 Million CHF | 19.77% |
| 2020 | 103.57 Million CHF | -10.33% |
| 2019 | 115.51 Million CHF | 2.9% |
| 2018 | 112.25 Million CHF | 21.36% |
| 2017 | 92.49 Million CHF | 52.54% |
| 2016 | 60.63 Million CHF | 820.07% |
| 2015 | -8.42 Million CHF | 29.1% |
| 2014 | -11.87 Million CHF | 4.2% |
| 2013 | -12.39 Million CHF | -130.32% |
| 2012 | -5.38 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 12.28 Million CHF | -78.03% |
| 2024 Q2 | 12.28 Million CHF | 0.0% |
| 2023 Q1 | 26.72 Million CHF | -66.36% |
| 2023 Q4 | 55.93 Million CHF | 24739.21% |
| 2023 Q3 | -227 Thousand CHF | -100.3% |
| 2023 Q2 | 74.9 Million CHF | 180.34% |
| 2023 FY | 130.84 Million CHF | 6.23% |
| 2022 Q1 | 2.79 Million CHF | -96.65% |
| 2022 Q4 | 79.43 Million CHF | 262.89% |
| 2022 Q3 | 21.88 Million CHF | -49.94% |
| 2022 Q2 | 43.72 Million CHF | 1467.31% |
| 2022 FY | 123.16 Million CHF | -0.72% |
| 2021 Q2 | 40.67 Million CHF | 8106.5% |
| 2021 Q4 | 83.37 Million CHF | 422.59% |
| 2021 FY | 124.05 Million CHF | 19.77% |
| 2021 Q1 | -508 Thousand CHF | -101.07% |
| 2021 Q3 | 15.95 Million CHF | -60.77% |
| 2020 FY | 103.57 Million CHF | -10.33% |
| 2020 Q1 | 6.15 Million CHF | -90.03% |
| 2020 Q4 | 47.33 Million CHF | 1642.01% |
| 2020 Q2 | 56.24 Million CHF | 814.22% |
| 2020 Q3 | -3.06 Million CHF | -105.46% |
| 2019 FY | 115.51 Million CHF | 2.9% |
| 2019 Q4 | 61.69 Million CHF | 1149.58% |
| 2019 Q1 | 1.48 Million CHF | -74.67% |
| 2019 Q3 | 4.93 Million CHF | -90.83% |
| 2019 Q2 | 53.81 Million CHF | 3516.6% |
| 2018 FY | 112.25 Million CHF | 21.36% |
| 2018 Q3 | 5.87 Million CHF | 364.95% |
| 2018 Q2 | -2.21 Million CHF | 0.0% |
| 2018 Q1 | -2.21 Million CHF | -120.16% |
| 2018 Q4 | 5.87 Million CHF | 0.0% |
| 2017 Q1 | 7.72 Million CHF | 51.27% |
| 2017 Q4 | 10.99 Million CHF | 0.0% |
| 2017 FY | 92.49 Million CHF | 52.54% |
| 2017 Q2 | 7.72 Million CHF | 0.0% |
| 2017 Q3 | 10.99 Million CHF | 42.35% |
| 2016 Q2 | 987.5 Thousand CHF | 0.0% |
| 2016 Q3 | 5.1 Million CHF | 417.11% |
| 2016 Q4 | 5.1 Million CHF | 0.0% |
| 2016 FY | 60.63 Million CHF | 820.07% |
| 2016 Q1 | 987.5 Thousand CHF | 330.72% |
| 2015 FY | -8.42 Million CHF | 29.1% |
| 2015 Q3 | -428 Thousand CHF | 86.61% |
| 2015 Q2 | -3.19 Million CHF | 0.0% |
| 2015 Q1 | -3.19 Million CHF | -37.59% |
| 2015 Q4 | -428 Thousand CHF | 0.0% |
| 2014 Q2 | -3.61 Million CHF | 0.0% |
| 2014 FY | -11.87 Million CHF | 4.2% |
| 2014 Q4 | -2.32 Million CHF | 0.0% |
| 2014 Q3 | -2.32 Million CHF | 35.74% |
| 2014 Q1 | -3.61 Million CHF | -17.24% |
| 2013 Q3 | -3.08 Million CHF | 1.02% |
| 2013 FY | -12.39 Million CHF | -130.32% |
| 2013 Q4 | -3.08 Million CHF | 0.0% |
| 2013 Q2 | -3.11 Million CHF | -0.0% |
| 2013 Q1 | -3.11 Million CHF | -4616.83% |
| 2012 FY | -5.38 Million CHF | 0.0% |
| 2012 Q3 | 68.97 Thousand CHF | 0.0% |
| 2012 Q4 | 68.97 Thousand CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | -1261.357% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 105402.975% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -9.85% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 41050.59% |
| Qrons Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 271220.413% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 5364593.645% |
| BioStem Technologies, Inc. | 15.42 Million USD | -748.242% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -74005.12% |
| CSL Limited | 7.56 Billion USD | 98.27% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 607.171% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -1017.717% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -93024.555% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -772.325% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -4217823.92% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -1235.92% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -198962.804% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 383233.236% |
| Mesoblast Limited | -35.16 Million USD | 472.043% |
| Marizyme, Inc. | 457.7 Thousand USD | -28486.285% |
| Genus plc | 178.7 Million USD | 26.782% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 40.555% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -210165.805% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -31799.358% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1189554.545% |
| ContraFect Corporation | -154 Thousand USD | 85061.039% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 261780.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -170351.141% |
| IMV Inc. | -962.29 Thousand USD | 13696.62% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 33865.074% |
| MultiCell Technologies, Inc. | 49.32 USD | -265287815.653% |
| ONE Bio Corp. | 20.12 Million USD | -550.122% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -224.947% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -267466.462% |
| Q BioMed Inc. | -8988.00 USD | 1455818.736% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -363.068% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 848388.382% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -194.965% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 11561.388% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -186814.286% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 2642264.782% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 134274.23% |
| GB Sciences, Inc. | -624.00 USD | 20968048.718% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 152190.017% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 62903946.154% |
| Enzolytics Inc. | 30.7 Thousand USD | -425977.895% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -27020.864% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 88.196% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 25530.021% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -21092.645% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 68.053% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 1477516.441% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 156142.41% |
| Kadimastem Ltd | -630.13 Thousand USD | 20863.706% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -13143.17% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1105634.432% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -74005.12% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -9540.841% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 451272.414% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -28972.777% |
| SYBLEU INC | 11.69 Thousand USD | -1118573.051% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -2739.41% |
| Bioxytran, Inc. | -8285.00 USD | 1579339.59% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 35177.748% |
| Neutra Corp. | 14.33 Thousand USD | -912631.078% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 159660.976% |
| PureTech Health plc | -1.6 Million USD | 8262.196% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 13167.848% |
| IXICO plc | 3.27 Million USD | -3901.223% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 18953.026% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 7405.416% |
| CSL Limited | 7.7 Billion USD | 98.302% |
| Cellectis S.A. | 18 Thousand USD | -726788.889% |